Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 16;10(32):11775-11788.
doi: 10.12998/wjcc.v10.i32.11775.

Quality of life and symptom distress after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Ya-Fen Wang  1 , Ting-Yao Wang  2 , Tzu-Ting Liao  3 , Meng-Hung Lin  4 , Tzu-Hao Huang  5 , Meng-Chiao Hsieh  6 , Vincent Chin-Hung Chen  7 , Li-Wen Lee  8 , Wen-Shih Huang  6 , Chao-Yu Chen  9   10
Affiliations

Quality of life and symptom distress after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Ya-Fen Wang et al. World J Clin Cases. .

Abstract

Background: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/ HIPEC) for peritoneal surface malignancy can effectively control the disease, however it is also associated with adverse effects which may affect quality of life (QoL).

Aim: To investigate early perioperative QoL after CRS/HIPEC, which has not been discussed in Taiwan.

Methods: This single institution, observational cohort study enrolled patients who received CRS/HIPEC. We assessed QoL using the Taiwanese version of the MD Anderson Symptom Inventory (MDASI-T) and European Organization Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30). Participants completed the questionnaires before CRS/HIPEC (S1), at the first outpatient follow-up (S2), and 3 mo after CRS/HIPEC (S3).

Results: Fifty-eight patients were analyzed. There was no significant perioperative difference in global health status. Significant changes in physical and role functioning scores decreased at S2, and fatigue and pain scores increased at S2 but returned to baseline at S3. Multiple regression analysis showed that age and performance status were significantly correlated with QoL. In the MDASI-T questionnaire, distress/feeling upset and lack of appetite had the highest scores at S1, compared to fatigue and distress/feeling upset at S2, and fatigue and lack of appetite at S3. The leading interference items were working at S1 and S2 and activity at S3. MDASI-T scores were significantly negatively correlated with the EORTC QLQ-C30 results.

Conclusion: QoL and symptom severity improved or returned to baseline in most categories within 3 mo after CRS/HIPEC. Our findings can help with preoperative consultation and perioperative care.

Keywords: Cytoreductive surgery; Hyperthermic intraperitoneal chemotherapy; Perioperative care; Peritoneal carcinomatosis; Quality of life; Symptom distress.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Figures

Figure 1
Figure 1
Flowchart of patient enrollment. CRS: cytoreductive surgery; HIPEC: hyperthermic intraperitoneal chemotherapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Albertsmeier M, Hauer A, Niess H, Werner J, Graeb C, Angele MK. Quality of life in peritoneal carcinomatosis: a prospective study in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) Dig Surg. 2014;31:334–340. - PubMed
    1. Chia CS, Tan GH, Lim C, Soo KC, Teo MC. Prospective Quality of Life Study for Colorectal Cancer Patients with Peritoneal Carcinomatosis Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol. 2016;23:2905–2913. - PubMed
    1. Ford J, Hanna M, Boston A, Berri R. Life after hyperthermic intraperitoneal chemotherapy; measuring quality of life and performance status after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. Am J Surg. 2016;211:546–550. - PubMed
    1. Shan LL, Saxena A, Shan BL, Morris DL. Quality of life after cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy for peritoneal carcinomatosis: A systematic review and meta-analysis. Surg Oncol. 2014;23:199–210. - PubMed
    1. Dodson RM, McQuellon RP, Mogal HD, Duckworth KE, Russell GB, Votanopoulos KI, Shen P, Levine EA. Quality-of-Life Evaluation After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol. 2016;23:772–783. - PMC - PubMed